Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep;15(9):342-347.
doi: 10.13107/jocr.2025.v15.i09.6120.

Role of Biomarkers in Diabetic Foot Osteomyelitis

Monika Gureh  1 , Ashok Kumar Attri  1 , Sanjay Gupta  1 , Jasbinder Kaur  2 , Mantu Jain  3
Affiliations

Role of Biomarkers in Diabetic Foot Osteomyelitis

Monika Gureh et al. J Orthop Case Rep. 2025 Sep.

Abstract

Introduction: Foot ulcer is one of the common problems in patients with diabetes mellitus. The spectrum of diabetic foot infection is wide, ranging from cellulitis and soft tissue infection to osteomyelitis (OM). OM requires further testing and investigations and even longer treatments. The aim of this prospective study was to assess the performance of serum markers, namely, the erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and procalcitonin (PCT) in the diagnosis and follow-up of patients with diabetic foot osteomyelitis (DFO) and to find correlation between serum levels of these biomarkers and treatment response.

Materials and methods: This prospective study was carried out in 50 patients. Diagnosis of OM was made by clinical examination and confirmed by radiological studies. The serum levels of ESR, CRP, and PCT were determined on admission in all the patients and then on day 15 and day 30 in the osteomyelitic group.

Results: No significant difference was observed in the levels of ESR, CRP, and PCT in DFO and non-OM patients (P > 0.05) at presentation. However, there was a significant difference (P > 0.05) in levels of these markers between patients with healed and non-healed lesions in the osteomyelitic group on day 15 and day 30.

Conclusion: Biomarkers may not help in diagnosing OM. However, the level of biomarkers decreases significantly in response to treatment validating their role in predicting healing.

Keywords: Biomarkers; diabetic foot; osteomyelitis; procalcitonin.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: Nil

Figures

Figure 1
Figure 1
Different kinds of diabetic foot ulcers.
Figure 2
Figure 2
Radiographic findings of the diabetic osteomyelitis.
Figure 3
Figure 3
Healing of the diabetic foot osteomyelitis at 15 days.
Figure 4
Figure 4
Healing of the diabetic foot osteomyelitis at 30 days.
See this image and copyright information in PMC

References

    1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4–14. - PubMed
    1. Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggesi A, Bakker K, et al. Optimal organization of health care in diabetic foot disease: Introduction to the Eurodiale study. Int J Low Extrem Wounds. 2007;6:11–7. - PubMed
    1. Nubé V, Bolton T, Chua E, Yue D. Osteomyelitis in the diabetic foot: What lies beneath. Primary Intention. 2007;15:49–57.
    1. Lipsky BA. A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab Res Rev. 2004;20(Suppl 1):S68–77. - PubMed
    1. Winkler E, Schöni M, Krähenbühl N, Uçkay I, Waibel FW. Foot osteomyelitis location and rates of primary or secondary major amputations in patients with diabetes. Foot Ankle Int. 2022;43:957–67. - PMC - PubMed

LinkOut - more resources